Posted in Immunotherapy

KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer

Posted by Manuela Boyle on 9 July 2021
KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer
Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer (LGSOC) who can benefit from targeted therapies. LGSOC, which accounts for between 1.02% and 3.64% of all ovarian carcinomas and 4.66% of serous ovarian carcinomas1, is molecularly unique from high-grade serous ovarian cancer (HGSOC) with approximately 70% of patients harboring a RAS pathway- associated mutation:...
Posted in:NewsCancerOvarian cancerImmunotherapy  

Associations

  • The Institute for Functional Medicine
  • Society for Integrative Oncology
  • American Society of Clinical Oncology
  • Australasian Integrative Medicine Association
  • Naturopaths and Herbalists Association of Australia